Pathogenetic Features and Current Management of Glioblastoma
Glioblastoma (GBM) is the most common form of primary malignant brain tumor with a devastatingly poor prognosis. The disease does not discriminate, affecting adults and children of both sexes, and has an average overall survival of 12–15 months, despite advances in diagnosis and rigorous treatment w...
Main Authors: | Hong-My Nguyen, Kirsten Guz-Montgomery, Devin B. Lowe, Dipongkor Saha |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/4/856 |
Similar Items
-
Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States Are Maintained in 3D Culture
by: Rochelle C. J. D’Souza, et al.
Published: (2020-01-01) -
Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy
by: Jang Hyun Park, et al.
Published: (2022-02-01) -
Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future
by: Rebecca Kringel, et al.
Published: (2023-07-01) -
Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
by: Masoumeh Najafi, et al.
Published: (2023-01-01) -
Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
by: Stephen C. Frederico, et al.
Published: (2023-02-01)